Core Viewpoint - Beijing Innotech Biotechnology Co., Ltd. plans to implement a restricted stock incentive plan for 2025 to enhance corporate governance, attract and retain talent, and align the interests of shareholders, the company, and core team members [1][2]. Group 1: Assessment Objectives - The plan aims to improve corporate governance and establish a long-term incentive mechanism to motivate the core team and promote the company's long-term development [1][2]. Group 2: Assessment Principles - The evaluation must adhere to principles of fairness, openness, and justice, closely linking the incentive plan to the performance and contributions of the incentivized individuals [2]. Group 3: Assessment Scope - The plan applies to all incentivized individuals confirmed by the Board's Compensation and Assessment Committee, including directors, senior management, and key technical personnel [2]. Group 4: Assessment Indicators and Standards - The performance assessment for the initial grant of restricted stocks will cover the years 2025 to 2027, focusing on company-level performance indicators [5][6]. - The performance assessment for 2025 will only consider the number of product registration certificates, while the 2027 assessment will focus on revenue growth [5][6]. Group 5: Performance Assessment Requirements - The performance assessment for the first grant requires achieving specific targets for product registration certificates and revenue growth, with a clear structure for determining the proportion of shares that can be vested based on performance [5][6][7]. Group 6: Assessment Period and Frequency - The assessment period for the initial grant is set for the three accounting years from 2025 to 2027, with annual evaluations for both company-level and individual-level performance [7]. Group 7: Assessment Procedures - The Board's Compensation and Assessment Committee will conduct annual assessments of the incentivized individuals and submit performance reports to the Board [7][8]. Group 8: Assessment Results Management - Individuals have the right to know their assessment results, and there is a process for addressing disputes regarding these results [8][9].

Core Viewpoint - The company is implementing a new stock incentive plan aimed at enhancing corporate governance, attracting and retaining talent, and aligning the interests of shareholders, the company, and core team members to promote long-term development [1][2]. Summary by Sections 1. Purpose of the Stock Incentive Plan - The plan aims to improve the corporate governance structure and establish a long-term incentive mechanism to attract and retain talent while ensuring shareholder interests are protected [1]. 2. Stock Incentive Method and Source of Shares - The incentive plan utilizes second-class restricted stocks, with eligible participants receiving shares at a set price upon meeting specific conditions. The shares will be sourced from market repurchases or directed issuance [2][3]. 3. Quantity of Restricted Stocks to be Granted - The plan proposes to grant a total of 2.112740 million restricted stocks, accounting for approximately 1.5483% of the company's total share capital. The initial grant will consist of 1.698240 million shares, representing 80.3809% of the total grant [3][4]. 4. Determination and Scope of Incentive Objects - Incentive objects include directors, senior management, and core technical personnel, excluding independent directors and supervisors. The selection is based on their direct impact on the company's performance and future development [5][6]. 5. Distribution of Restricted Stocks - The distribution of restricted stocks among incentive objects is detailed, ensuring that no individual receives more than 1.00% of the total share capital through all incentive plans [7][8]. 6. Validity Period of the Incentive Plan - The plan will be valid from the date of the first grant of restricted stocks until all granted stocks are vested or become invalid, with a maximum duration of 60 months [9]. 7. Conditions for Granting and Vesting of Restricted Stocks - Specific conditions must be met for granting and vesting, including financial performance criteria and compliance with legal regulations. The vesting schedule is structured over multiple periods [16][18]. 8. Performance Assessment Criteria - The performance assessment will focus on revenue growth and the number of product registration certificates obtained, with specific targets set for each assessment year [19][20]. 9. Adjustment Methods for Granting and Vesting - The plan includes provisions for adjusting the number and price of restricted stocks in response to corporate actions such as stock splits or capital increases [27][28]. 10. Accounting Treatment and Impact on Performance - The company will account for the stock incentive plan in accordance with relevant accounting standards, ensuring that the costs and impacts on financial performance are accurately reflected [30].

证券代码：688253 证券简称：英诺特 公告编号：2025-044 北京英诺特生物技术股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 表决结果：同意 3 票，弃权 0 票，反对 0 票，表决通过。 北京英诺特生物技术股份有限公司（以下简称"公司"）第二届监事会第十 次会议于 2025 年 8 月 27 日以现场结合通讯方式召开。会议通知已于 2025 年 8 月 17 日以书面或通讯方式送达各位监事，各位监事已经知悉与所议事项相关的 必要信息。公司应出席监事 3 名，实际出席监事 3 名，会议由监事会主席李松岭 主持。本次会议的召集、召开及表决程序符合《中华人民共和国公司法》和《北 京英诺特生物技术股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事审议并记名投票表决，会议通过以下议案： （一）审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 表决结果：同意 3 票，弃权 0 票，反对 0 票，表决通过 ...

Group 1 - The company will hold its 2025 First Extraordinary General Meeting on September 15, 2025, at 14:45 in Beijing [2][6] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each [1][2] - The agenda includes several non-cumulative voting proposals, such as changes to registered capital and the implementation of a stock incentive plan [2][8] Group 2 - The company will utilize the Shanghai Stock Exchange's network voting system for shareholder participation [2][4] - Shareholders must register for the meeting by providing necessary documentation, including identity verification [5][6] - The company aims to enhance participation from small and medium investors by offering reminder services for the meeting [4][6]

Investment Overview - The company plans to use up to RMB 300 million of temporarily idle raised funds for cash management, which can be rolled over within this limit [1][6] - The purpose of this investment is to enhance the efficiency of fund utilization without affecting the normal operation of the company's main business or the implementation of investment projects [1][4] Fundraising and Management - The company successfully raised a net amount of RMB 800.48 million from its initial public offering (IPO) of 34,020,000 shares, with all funds in place [2] - The balance of the raised funds in the special account as of June 30, 2025, was RMB 311.32 million, indicating some funds are temporarily idle [3] Investment Strategy - The company will invest in safe, liquid, and principal-protected financial products, such as time deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [3][4] - Cash management will be conducted through a special account for raised funds or a publicly disclosed dedicated settlement account [3] Risk Management - The company acknowledges potential market risks affecting returns but will manage investments based on economic conditions and market changes [4] - The cash management strategy complies with relevant regulations and internal policies, ensuring that the investment does not alter the intended use of the raised funds [4][6] Approval Process - The board of directors and the supervisory board approved the cash management proposal on August 27, 2025, and the supervisory board expressed clear consent [5][6] - The approval process adheres to legal requirements and regulatory standards, ensuring no adverse impact on shareholder interests [6][7] Institutional Opinions - The supervisory board and the sponsor institution, Huatai United Securities, agree that the cash management of idle funds is appropriate and does not affect the company's normal operations or investment projects [6][7]

Core Viewpoint - The company plans to use part of the surplus raised funds for other investment projects and to postpone certain investment projects, which aligns with its strategic development and aims to enhance the efficiency of fund utilization [1][10][11]. Fundraising Basic Situation - The company raised a net amount of RMB 800.48 million from its initial public offering of 34,020,000 shares, with all funds accounted for and managed in a dedicated account [1][2]. - The funds were subject to strict regulatory oversight as per relevant guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][10]. Investment Project Situation - Due to the net amount raised being lower than initially planned, the company adjusted the investment amounts for its projects to ensure efficient use of funds [2][5]. - The company has terminated certain projects, including the "In Vitro Diagnostic Product R&D and Industrialization Project (Phase I)" as of April 2024, and has made adjustments to other projects [2][5][9]. Use of Surplus Funds - The company intends to allocate RMB 60 million of the surplus funds towards the "In Vitro Diagnostic Product R&D Project," focusing on international market expansion and collaboration with Quanterix Corporation for advanced detection technologies [5][9]. - The surplus funds will also support the development of products for the EU IVDR and US FDA markets, enhancing the company's competitive position [5][9]. Project Postponement - The timeline for the "In Vitro Diagnostic Product R&D Project" has been extended from October 2025 to April 2027 to accommodate the current progress and ensure effective fund utilization [9][10]. Impact on the Company - The adjustments made in the use of surplus funds and project timelines are expected to optimize resource allocation and enhance operational efficiency without adversely affecting the company's core business [9][10]. Review and Decision Procedures - The company’s board and supervisory committee have approved the use of surplus funds, which will be submitted for shareholder approval, ensuring compliance with regulatory requirements [10][11].

北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 法律意见书 二〇二五年八月 北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 法律意见书 致：北京英诺特生物技术股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京英诺特生物技术股份有 限公司（以下简称"英诺特"或"公司"）委托，就公司 2023 年限制性股票激励计 划（以下简称"激励计划"或"本激励计划"）相关事宜担任专项法律顾问，并就本 激励计划出具本法律意见书。 为出具本法律意见书，本所律师审阅了《北京英诺特生物技术股份有限公司 京英诺特生物技术股份有限公司 2023 年限制性股票激励计划实施考核管理办 法》（以下简称"《考核办法》"）、公司相关董事会会议文件以及本所律师认为需 要审查的其他文件，并通过查询政府部门公开信息对相关的事实和资料进行了核 查和验证。 为出具本法律意见书，本所律师根据有关法律、行政法规、规范性文件的规 定和本所业务规则的要求，本着审慎性及重要性原则对本激励计划的有关的文件 资料和事实进行了核查和验证。 -1- 对本法律意见书，本所律师作出如下声明： 提供了本所律师认为制作法律意见书所必需的原始书面材料、 ...

北京英诺特生物技术股份有限公司 内部控制评价制度 （2025年8月修订） 北京英诺特生物技术股份有限公司 内部控制评价制度 第一章 总则 第四条 公司实施内部控制评价至少应遵循下列原则： （一）全面性原则。评价工作应当包括内部控制的设计与运行， 涵盖公司及所属单位的各种业务和事项。 （二）重要性原则。评价工作应当在全面评价的基础上，关注重 要业务单位、重大业务事项和高风险领域。 （三）客观性原则。评价工作应当准确地揭示经营管理的风险状 况，如实反映内部控制设计与运行的有效性。 第一条 为规范北京英诺特生物技术股份有限公司（以下简称"公 司"）内部控制评价工作，确保内部控制有效运行，依据《中华人民 共和国公司法》、《企业内部控制基本规范》及其配套指引等法律法 规的规定，并结合本公司实际情况，制定本制度。 （四）制衡性原则。内部控制制度保证公司机构、岗位及其职责 权限的合理设置和分工，坚持不相容职务相互分离，确保不同机构和 岗位之间权责分明、相互制约、相互监督，同时兼顾运营效率。 第二条 本制度所称内部控制评价，是指由公司董事会和管理层 实施的，对公司内部控制有效性进行全面评价，形成评价结论，出具 评价报告的过程 ...

第二条 董事会审计委员会是董事会下设的专门委员会，主要负 责审核公司财务信息及其披露、监督及评估内外部审计工作和内部控 制，对董事会负责。内部审计部门对审计委员会负责，向审计委员会 报告工作。 第三条 公司不设监事会或者监事，由审计委员会行使《公司法》 规定的监事会的职权。 第二章 人员组成 北京英诺特生物技术股份有限公司 董事会审计委员会议事规则 （2025 年 8 月修订） 北京英诺特生物技术股份有限公司 董事会审计委员会议事规则 第一章 总则 第一条 为提供北京英诺特生物技术股份有限公司（以下简称"公 司"）董事会决策的依据，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司 法》、《中华人民共和国证券法》、《上市公司治理准则》、《上海 证券交易所科创板股票上市规则》、《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》、《上市公司独立董事管理办 法》和《北京英诺特生物技术股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，制定本议事规则。 第三章 职责权限 第八条 审计委员会的主要职责包括： （一）监督及评估外部审计工作，提议聘请 ...

Core Viewpoint - The document outlines the insider information management system of Beijing Innotech Biotechnology Co., Ltd, emphasizing the importance of confidentiality and compliance with relevant laws and regulations to protect investors' rights and ensure fair information disclosure [1][2]. Group 1: Insider Information Management - The company's board of directors is responsible for managing insider information and must ensure the accuracy and completeness of insider information registries [2]. - Insider information includes any undisclosed information that could significantly impact the company's operations, finances, or stock prices [3]. - The company must maintain a record of all individuals who have access to insider information, including their relationship to the company and the specifics of the information they received [4][5]. Group 2: Responsibilities of Insider Information Holders - Individuals with access to insider information are required to maintain confidentiality and are prohibited from engaging in insider trading or disclosing such information [3][12]. - The company must ensure that the number of individuals with access to insider information is minimized before public disclosure [19]. - Any breach of confidentiality by insider information holders may result in disciplinary actions, including termination and legal consequences [12][14]. Group 3: Reporting and Documentation - The company is required to submit insider information registries and significant event progress memos to the Shanghai Stock Exchange within five trading days after public disclosure [12]. - The documentation must include detailed records of all stages of significant events, including discussions, negotiations, and decisions made [7][8]. - The company must keep insider information registries and significant event progress memos for at least ten years [11].